EGFR and gastric cancer: Other phase I trials seek to test combinations of volitinib and docetaxel in gastric cancer (NCT02252913) and volitinib and gefitinib for EGFR TKI-resistant NSCLC in patients with mutant EGFR (NCT02374645).